source
- Experts urge FDA to require credentials for psychedelic therapy providersAt a recent public hearing, mental health experts called on the FDA to adopt safety measures as it pushes to speed up psychedelic therapy development. The experts specifically recommended that pro…
- Connect Biopharma's asthma drug rademikibart misses primary endpoint in Phase 2 trialConnect Biopharma reported that its IL-4/IL-13 blocker rademikibart failed to meet the primary endpoint in a Phase 2 study in asthma patients with type-2 inflammation. The trial enrolled 160 patie…